Commentary

Video

Other Potential Roles for Luspatercept in MDS And Beyond

Author(s):

Amer Zeidan, MBBS,Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Related Videos
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Floortje J. Backes, MD, discusses data for mirvatuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer
Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.
Floortje J Backes, MD, discusses how mirvatuximab soravtansine has affected the management of platinum-resistant ovarian cancer.
Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.
Dr Sekkeres on the Association Between Smoking and Disease Progression in MDS
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Related Content
Yale Cancer Center | Image Credit: © Bantita - stock.adobe.com.
February 6th 2025

Yale Medicine Takes Top Spots in National, State Rankings

Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center
February 3rd 2025

Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

Polycythemia Vera | Image Credit: © ChaoticMind – stock.adobe.com
February 5th 2025

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

Ferdinandos Skoulidis, MD
February 3rd 2025

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

The OncFive: OncLive's Top Oncology Articles for the Week of 1/19
January 25th 2025

The OncFive: Top Oncology Articles for the Week of 1/19